Text Size

A Degradable Sustained-Release Drug Delivery System for Bleb-Forming Glaucoma Surgery

van Mechelen RJS, Wolters JEJ, Fredrich S, Bertens CJF, Gijbels MJJ, Schenning APHJ, Pinchuk L, Gorgels TGMF, Beckers HJM


  • 2023
  • Macromol Biosci
View publication
  • Therapeutic Area

    Glaucoma

  • Technology

    Drug Delivery

  • Categories

    Preclinical development

  • Affiliations

    University Eye Clinic Maastricht, Maastricht University Medical Center+ (MUMC+), Maastricht, 6202 AZ, The Netherlands; School for Mental Health and Neuroscience, Maastricht University, Maastricht, 6229 ER, The Netherlands; Department of Medical Biochemistry, Experimental Vascular Biology, Amsterdam Cardiovascular Sciences, Amsterdam Infection and Immunity, Amsterdam UMC, A.M. Vree G1-146, Amsterdam, 1100 DD, Netherlands; Laboratory of Stimuli-responsive Functional Materials and Devices, Department of Chemical Engineering and Chemistry, Technical University of Eindhoven, Eindhoven, 5600 MB, The Netherlands; InnFocus Inc. a Santen company, 12415 S.W. 136 Avenue, Miami, FL, 33186, USA

Related Publications

Long-term safety and efficacy of sepetaprost, with or without timolol, in patients with open-angle glaucoma or ocular hypertension: results from the randomised, phase 3 ANGEL-J2 study

Inatani M., Tone Y., Ikeda T., Angeles R.


Efficacy and safety of sepetaprost in patients with primary open-angle glaucoma or ocular hypertension: results from the randomised, phase 3 ANGEL-J1 study

Inatani M., Kanamori A., Inai M., Ikeda T., Angeles R.


Clinical outcomes of Preserflo MicroShunt implant procedure in open‑angle glaucoma patients – a 1000 eyes case-series; including subanalysis of combined cataract-glaucoma surgery and standalone surgery in pseudophakic eyes

Klabe, K.; Werth, J.P.; Kaymak, H. ; Fricke, A.


Can't find what you're looking for?

Contact us

Document number: NP-No product-EMEA-0110
Date of preparation: February 2022